Future Medicine Statistics
Total Valuation
Future Medicine has a market cap or net worth of KRW 10.65 billion.
| Market Cap | 10.65B |
| Enterprise Value | n/a |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
Future Medicine has 9.28 million shares outstanding.
| Current Share Class | 9.28M |
| Shares Outstanding | 9.28M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +35.88% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 10.65 |
| PB Ratio | 1.63 |
| P/TBV Ratio | 1.79 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.62, with a Debt / Equity ratio of 0.03.
| Current Ratio | 9.62 |
| Quick Ratio | 9.08 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.03 |
| Interest Coverage | -4.55 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -100.42% |
| Revenue Per Employee | 38.46M |
| Profits Per Employee | -514.10M |
| Employee Count | 26 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -49.09% in the last 52 weeks. The beta is -0.05, so Future Medicine's price volatility has been lower than the market average.
| Beta (5Y) | -0.05 |
| 52-Week Price Change | -49.09% |
| 50-Day Moving Average | 1,545.22 |
| 200-Day Moving Average | 1,517.82 |
| Relative Strength Index (RSI) | 29.98 |
| Average Volume (20 Days) | 4,227 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Future Medicine had revenue of KRW 1.00 billion and -13.37 billion in losses. Loss per share was -1,637.42.
| Revenue | 1.00B |
| Gross Profit | 1.00B |
| Operating Income | -7.09B |
| Pretax Income | -13.37B |
| Net Income | -13.37B |
| EBITDA | -6.64B |
| EBIT | -7.09B |
| Loss Per Share | -1,637.42 |
Balance Sheet
The company has 5.41 billion in cash and 226.27 million in debt, giving a net cash position of 5.18 billion or 558.86 per share.
| Cash & Cash Equivalents | 5.41B |
| Total Debt | 226.27M |
| Net Cash | 5.18B |
| Net Cash Per Share | 558.86 |
| Equity (Book Value) | 6.52B |
| Book Value Per Share | 703.11 |
| Working Capital | 5.21B |
Cash Flow
In the last 12 months, operating cash flow was -7.09 billion and capital expenditures -110.72 million, giving a free cash flow of -7.20 billion.
| Operating Cash Flow | -7.09B |
| Capital Expenditures | -110.72M |
| Free Cash Flow | -7.20B |
| FCF Per Share | -776.78 |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -708.92% |
| Pretax Margin | -1,336.67% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Future Medicine does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -125.53% |
| FCF Yield | -67.66% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Future Medicine has an Altman Z-Score of -10.89 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -10.89 |
| Piotroski F-Score | 1 |